Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro(TM)) on a new test of PAF procoagulant activity of whole blood.

Thrombosis Research

Volumn 86, Issue 3, 1997, Pages 205-219

  Despotis, George J ^a   Ikonomakou, Stavroula ^a   Levine, Vladimir ^a   Joiner Maier, Diane ^c   Santoro, Samuel A ^a,b   Heinrich Joist, J ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Coagulation; Monitoring; Platelet count; Platelet procoagulant function; Surgery, cardiac; White blood cell counts

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN;

ARTICLE; BLOOD; BLOOD CLOTTING; CONTROLLED STUDY; HUMAN; HUMAN CELL; LABORATORY TEST; LEUKOCYTE COUNT; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; EVALUATION STUDIES; HEMOSTASIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LEUKOCYTE COUNT; PLATELET ACTIVATING FACTOR; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; REFERENCE VALUES;

EID: 0030973469     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00064-9     Document Type: Article

References (35)

1. WOODMAN RC, HARKER LA. Bleeding complications associated with cardiopulmonary bypass. [Review]. Blood 76, 1680-1697, 1990.
2. KHURI SF, WOLFE JA, JOSA M, AXFORD TC, SZYMANSKI I, ASSOUSA S, RAGNO G, PATEL M, SILVERMAN A, PARK M. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 104, 94-107, 1992.
3. GEORGE JN, SHATTIL SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 324, 27-39, 1991.
4. DESPOTIS GJ, FILOS K, LEVINE V, GOODNOUGH LT, SANTORO S. Evaluation of a new, point-of-care test that evaluates PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 55, 1311-1323, 1996.
5. KLINDWORTH, J.T., MACVEIGH, I., ERETH, M.H. The platelet activated clotting test (PACT) predicts platelet dysfunction associated with cardiopulmonary bypass (CPB). Anesth Analg 82, 99-100, 1996, (Abstract)
6. RINDER CS, BOHNERT J, RINDER HM, MITCHELL J, AULT K, HILLMAN R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 75, 388-393, 1991.
7. MOOREHEAD MT, WESTENGARD JC, BULL BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 63, 394-398, 1984.
8. MOLITERNO DJ, CALIFF RM, AGUIRRE FV, ANDERSON K, SIGMON KN, WEISMAN HF, TOPOL EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 75, 559-562, 1995.
9. SWEENEY JD, LABUZETTA JW, FITZPATRICK JE. The effect of the platelet count on the aggregation response and adenosine triphosphate release in an impedance lumi-aggregometer. Am J Clin Pathol 89, 655-659, 1988.
10. COLLER BS, ANDERSON K, WEISMAN HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 74, 302-308, 1995.
11. SHIGETA O, GLUSZKO P, DOWNING SW, LU W, NIEWIAROWSKIS, EDMUNDS LH, JR. Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Circulation 86, 11398-404, 1992.
12. GOLD HK, GIMPLE LW, YASUDA T, LEINBACH RC, WERNER W, HOLT R, JORDAN R, BERGER H, COLLEN D, COLLER BS. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 86, 651-659, 1990.
13. CHRISTOPOULOS C, MACKIE I, LAHIRI A, MACHIN S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 4, 729-737, 1993.
14. BOEHRER JD, KEREIAKES DJ, NAVETTA FI, CALIFF RM, TOPOL EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. Am J Cardiol 74, 1166-1170, 1994.
15. AGUIRRE FV, TOPOL EJ, FERGUSON JJ, ANDERSON K, BLANKENSHIP JC, HEUSER RR, SIGMON K, TAYLOR M, GOTTLIEB R, HANOVICH G, ET AL. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 91, 2882-2890, 1995.
16. REVERTER JC, KESSELS H, BEGUIN S, KUMAR R, HEMKER HC, COLLER BS. Platelet glycoprotein IIb/IIIa inhibition decreases thrombin generation-induced by tissue factor. Blood 84, 470A1994.
17. GALLISTL S, MUNTEAN W, LEIS HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost 74, 1163-1168, 1995.
18. FERNANDEZ F, N'GUYEN P, VAN RYN J, OFOSU FA, HIRSH J, BUCHANAN MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43, 491-495, 1986.
19. JOHN LC, REES GM, KOVACS IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 105, 816-822, 1993.
20. BASIC-MICIC M, BREDDIN HK. Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion. Semin Thromb Hemost 22-28, 1993.
21. SUZUKI K, NISHIOKA J, HASHIMOTO S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta 585, 416-426, 1979.
22. SOBEL M, MCNEILL PM, CARLSON PL, KERMODE JC, ADELMAN B, CONROY R, MARQUES D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. Journal of Clinical Investigation 87, 1787-1793, 1991.
23. CARR ME, JR., CARR SL, HANTGAN RR, BRAATEN J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 73, 499-505, 1995.
24. COLLER, B.S., SCUDDER, L.E., LANG, D. A rapid, whole blood, bedside assay to monitor platelet glycoprotein (GP) IIb/IIIa blockade. Blood 1994, 474A1996, (Abstract)
25. HANAHAN DJ, BUXTON D, HALVORSEN O, OLSON MS. Platelet-activating factor: a unique lipid chemical mediator. Adv Prostaglandin Thromboxane Leukot Res 15, 707-709, 1985.
26. MACCONI D, FOPPOLO M, PARIS S, NORIS M, AIELLO S, REMUZZI G, REMUZZI A. PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. Am J Physiol 269, C42-47, 1995.
27. RAFF GW, SPILLERT CR, WILSON DJ, LAZARO EJ. Procoagulant property of platelet activating factor (PAF). Agents Actions 39, C1061993.
28. ROTLLAN E, ESCOLAR G, ORDINAS A, BASTIDA E. [Effect of PAF (platelet-activating factor) on hemostasis. Studies on endothelial cells and platelets]. Sangre (Bare) 38, 115-119, 1993.
29. PERUSSIA B, JANKIEWICZ J, TRINCHIERI G. Binding of platelets to human monocytes: a source of artifacts in the study of the specificity of antileukocyte antibodies. J Immunol Methods 50, 269-276, 1982.
30. NGUY''EN P, PETITFRERE E, POTRON G. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. Thromb Res 78, 33-42, 1995.
31. ALTIERI DC, MANNUCCI PM, CAPITANIO AM. Binding of fibrinogen to human monocytes. J Clin Invest 78, 968-976, 1986.
32. DRAKE TA, RUF W, MORRISSEY JH, EDGINGTON TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 109, 389-395, 1989.
33. ALTIERI DC, EDGINGTON TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 263, 7007-7015, 1988.
34. GABOURY J, WOODMAN RC, GRANGER DN, REINHARDT P, KUBES P. Nitric oxide prevents leukocyte adherence: role of superoxide. Am J Physiol 265, H862-7, 1993.
35. RINDER HM, BONAN JL, RINDER CS, AULT KA, SMITH BR. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991 78, 1730-1737, 1991.